Business Context and Reporting Period
This Form 8-K, filed on September 21, 2023, reports material events for iBio, Inc. (IBIO) occurring on September 15 and September 18, 2023. The Company, a Delaware corporation, operates a cGMP biologics manufacturing facility in Bryan, Texas. The filing details a strategic asset sale and a corresponding amendment to its credit facility to address liquidity and debt maturity concerns.
Key Financial Metrics
- Asset Sale Price: $17,250,000 for the Bryan, TX manufacturing facility (Property).
- Cash Position (Preliminary): Approximately $7.6 million as of June 30, 2023 (including $3.3 million restricted cash).
- Debt Obligations: Term note principal balance was approximately $13.1 million as of June 30, 2023, and $12,688,817.05 as of September 15, 2023.
- Net Loss (Preliminary): Estimated between $29.0 million and $29.5 million for the twelve months ended June 30, 2023.
- Outstanding Shares: Approximately 20.3 million common shares as of June 30, 2023.
Material Changes and Agreements
Purchase and Sale Agreement
On September 15, 2023, iBio CDMO LLC entered into an agreement to sell its Bryan, TX facility to Majestic Realty Co. for $17.25 million. The transaction includes the ground leasehold, buildings, improvements, and equipment. The closing is targeted for December 1, 2023, subject to due diligence approval by October 16, 2023, and Texas A&M University System approval by November 13, 2023.
Credit Agreement Amendment
On September 18, 2023, the Company amended its Credit Agreement with Woodforest National Bank. Key changes include:
- Setting the term loan maturity date to December 31, 2023.
- Mandating that net proceeds from the facility sale be used immediately to satisfy the term loan.
- Allowing the fiscal year 2023 filing to be accepted with or without a "going concern" designation, contingent on the sale agreement execution.
- Imposing a $20,000 fee if the facility is not sold by December 1, 2023.
Comparison to Prior Period
The preliminary net loss for the twelve months ended June 30, 2023 ($29.0M–$29.5M) is slightly lower than the $29.6 million loss in the prior year, which included approximately $1.9 million in litigation settlement revenue. Cash reserves declined significantly from $28.7 million in June 2022 to $7.6 million in June 2023. Outstanding shares increased from 8.7 million to 20.3 million over the same period.
Outlook, Risks, and Contingencies
The Company's ability to repay its term loan upon maturity on December 31, 2023, is critically dependent on the successful closing of the facility sale. Management states there can be no assurance the sale will close in a timely manner or at all. If the sale fails to close by the loan maturity date, the Company is unlikely to have sufficient funds to repay the debt, potentially leading to foreclosure on the facility and severe disruption to operations. Additionally, the Company will incur transaction expenses regardless of whether the sale is completed.
Investor Verification Checklist
- Verify the status of the "Property Approval Notice" deadline (October 16, 2023) and the "TAMU Approval" deadline (November 13, 2023).
- Confirm the exact outstanding principal balance of the Woodforest National Bank term loan as of the most recent date.
- Review the unaudited pro forma financial information (Exhibit 99.1) to understand the projected impact of the asset sale on the balance sheet.
- Monitor for any announcements regarding the "going concern" qualification in the upcoming Form 10-K.
- Assess the liquidity runway if the facility sale is terminated or delayed beyond December 31, 2023.